Elafibranor · Iqirvo
Small molecule
Also known as GFT505
Evidence outlook
Approved: Primary Biliary Cholangitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- IQIRVO® (elafibranor) is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Marketing authorization with conditions for this indication is based on a randomized, placebo- controlled, phase III study that assessed alkaline phosphatase (ALP) and bilirubin as a composite biochemical surrogate endpoint (see 14 CLINICAL TRIALS).
- Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ELSPIRE NCT06383403 · Primary Biliary Cholangitis Registry: NCT06383403 | 3 | Percentage of participants with normalisation of Alkaline Phosphate (ALP) Levels (At Week 52) 2026-06-16 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 2 more trials
ELFIDENCE NCT06016842 · Primary Biliary Cholangitis Registry: NCT06016842 | 3 | Event-free survival (From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)) 2029-05-31 | In progress: results expected 31 May 2029 | not yet graded | link ↗ |
ELATIVE NCT04526665 · Primary Biliary Cholangitis The study was randomized, quadruple-blind, placebo-controlled, and included 161 participants, but its primary endpoint was a biochemical cholestasis-response measure rather than a clinical event or symptom outcome. The primary comparison was statistically significant in favor of elafibranor, although no power calculation is reported in the provided record. Registry: NCT04526665 | 3 | Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 2023-06-01 | Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Primary Biliary Cholangitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elafibranor (Iqirvo): this drug | Approved | Small molecule | PPAR-alpha/PPAR-delta | Partial signal | NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8) | |
| Seladelpar (Livdelzi) | Approved | Small molecule | PPAR-delta | Partial signal | NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02). NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results). | |
| Saroglitazar (Lipaglyn) | Phase 3 | Small molecule | PPAR-alpha/PPAR-gamma | Partial signal | NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29). | |
| Pemafibrate (Parmodia) | Phase 2 | Small molecule | PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Setanaxib | Phase 2 | Small molecule | NOX1/4 | not yet graded | No reviewed efficacy summary in this indication | |
| Volixibat | Phase 2 | Small molecule | Ileal bile acid transporter (IBAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Iqirvo (Elafibranor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent